CN102144163A - 关于鉴定和使用靶向癌症干细胞的试剂的方法 - Google Patents

关于鉴定和使用靶向癌症干细胞的试剂的方法 Download PDF

Info

Publication number
CN102144163A
CN102144163A CN2009801219225A CN200980121922A CN102144163A CN 102144163 A CN102144163 A CN 102144163A CN 2009801219225 A CN2009801219225 A CN 2009801219225A CN 200980121922 A CN200980121922 A CN 200980121922A CN 102144163 A CN102144163 A CN 102144163A
Authority
CN
China
Prior art keywords
cells
cancer
compound
cell
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801219225A
Other languages
English (en)
Chinese (zh)
Inventor
P·古普塔
T·T·昂德尔
E·S·兰德尔
R·温伯格
S·马尼
M-J·廖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Original Assignee
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research filed Critical Massachusetts Institute of Technology
Publication of CN102144163A publication Critical patent/CN102144163A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
CN2009801219225A 2008-04-10 2009-04-10 关于鉴定和使用靶向癌症干细胞的试剂的方法 Pending CN102144163A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4394808P 2008-04-10 2008-04-10
US61/043,948 2008-04-10
US5356308P 2008-05-15 2008-05-15
US61/053,563 2008-05-15
PCT/US2009/002254 WO2009126310A2 (en) 2008-04-10 2009-04-10 Methods for identification and use of agents targeting cancer stem cells

Publications (1)

Publication Number Publication Date
CN102144163A true CN102144163A (zh) 2011-08-03

Family

ID=41162467

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801219225A Pending CN102144163A (zh) 2008-04-10 2009-04-10 关于鉴定和使用靶向癌症干细胞的试剂的方法

Country Status (6)

Country Link
US (2) US20110191868A1 (https=)
EP (2) EP2274617A4 (https=)
JP (2) JP2011522515A (https=)
CN (1) CN102144163A (https=)
CA (1) CA2723648A1 (https=)
WO (1) WO2009126310A2 (https=)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243074A (zh) * 2012-02-14 2013-08-14 中国科学院动物研究所 一种人结直肠癌肿瘤细胞系及其制备方法和应用
CN104725511A (zh) * 2015-02-16 2015-06-24 华南农业大学 一种猪肠道干细胞的分离培养方法
CN104840961A (zh) * 2014-02-14 2015-08-19 马立伟 癌症干细胞敏感剂在制备抗癌症干细胞试剂盒中的应用
CN106461676A (zh) * 2014-03-17 2017-02-22 新加坡科技研究局 基于核因子κB易位预测化合物的毒性的方法
CN106701886A (zh) * 2016-12-16 2017-05-24 管晓翔 一种三阴性乳腺癌细胞上皮间质转换过程中对内皮细胞分泌功能影响的检测方法
CN108410986A (zh) * 2018-02-26 2018-08-17 中国人民解放军总医院 Cdh6促进骨肉瘤生长和转移
CN108513537A (zh) * 2015-09-23 2018-09-07 米纳瓦生物技术公司 筛选分化干细胞的试剂的方法
CN110082536A (zh) * 2019-04-17 2019-08-02 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用
CN111278443A (zh) * 2017-11-08 2020-06-12 丹娜法伯癌症研究院 使用rhoa显性负型治疗癌症的组合物和方法
CN111886499A (zh) * 2017-12-21 2020-11-03 瓦尔希伯伦私人肿瘤研究基金会 基于检测肿瘤细胞中rad51焦点的方法
CN112730840A (zh) * 2021-01-29 2021-04-30 章毅 鉴别cd44和cd24分子表型的方法
CN113125689A (zh) * 2021-03-29 2021-07-16 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用
CN114181102A (zh) * 2021-11-10 2022-03-15 深圳市检验检疫科学研究院 己雷琐辛半抗原、人工抗原、抗体及其合成方法和应用
CN115948558A (zh) * 2023-01-19 2023-04-11 重庆医科大学 乳腺癌肺特异性转移的标志物及其药物组合物与应用
CN115992240A (zh) * 2022-10-28 2023-04-21 中山大学附属第三医院 E2f转录因子2作为治疗靶点在制备预防和/或治疗多发性骨髓瘤的药物中的应用
CN116286658A (zh) * 2022-09-26 2023-06-23 南通大学 Traf5抑制剂在制备人恶性黑色素瘤治疗药物中的应用
CN116783487A (zh) * 2020-08-05 2023-09-19 乔斯林糖尿病中心公司 终末期肾病生物标记物组

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2579909T3 (es) 2009-02-03 2016-08-17 Koninklijke Nederlandse Akademie Van Wetenschappen Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US20120295346A1 (en) * 2009-07-22 2012-11-22 Tufts University Methods and compositions for modulating membrane potential to influence cell behavior
EP2322927A1 (en) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
US8815581B2 (en) 2010-02-03 2014-08-26 Samsung Life Public Welfare Foundation Method for proliferating stem cells by activating c-MET/HGF signaling and notch signaling
EP2561356B1 (en) 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US10095842B2 (en) * 2010-05-28 2018-10-09 Salgomed, Inc. Methods for artificial combinatorial control of biological systems
US20110293525A1 (en) * 2010-05-29 2011-12-01 Board Of Trustees Of The University Of Illinois Tumor stem cells
WO2012018857A2 (en) * 2010-08-02 2012-02-09 The Broad Institute Of Mit And Harvard Prediction of and monitoring cancer therapy response based on gene expression profiling
JP2013536689A (ja) 2010-09-01 2013-09-26 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ Ｅｍｔを調節するための組成物および方法ならびにその使用
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2611463A2 (en) 2010-09-03 2013-07-10 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
GB201100180D0 (en) * 2011-01-06 2011-02-23 Capsant Neurotechnologies Ltd Tumour cell and tissue culture
FR2970179B1 (fr) 2011-01-11 2013-01-18 Centre Nat Rech Scient Moyens pour reduire ou eradiquer le pouvoir tumoral de cellules souches cancereuses et/ou metastasiques
WO2013105985A1 (en) 2011-02-28 2013-07-18 Philadelphia Health & Education Corporation Small molecule inhibitors of rad51 recombinase and methods thereof
US20130331381A1 (en) 2011-02-28 2013-12-12 Mcmaster University Treatment of Cancer WIth Dopamine Receptor Antagonists
ES2586599T3 (es) * 2011-03-24 2016-10-17 The Rogosin Institute Ensayo para cribar compuestos que disminuyen selectivamente el número de células madre de cáncer
CN103562723B (zh) * 2011-03-27 2017-04-26 欧恩克斯特姆诊断学（毛里求斯）私人有限公司 用于识别肿瘤细胞的标记、方法及其试剂盒
WO2012150543A1 (en) 2011-05-02 2012-11-08 Universite De Geneve Macrocyclic lactones and use thereof
WO2012167101A1 (en) * 2011-06-03 2012-12-06 The General Hospital Corporation Ovarian cancer stem cells and methods of isolation and uses thereof
DK2729806T3 (en) 2011-07-08 2017-05-15 Sloan-Kettering Inst For Cancer Res APPLICATIONS OF MARKED HSP90 INHIBITORS
WO2013032907A1 (en) * 2011-08-26 2013-03-07 The Broad Institute, Inc. Compounds and methods for the treatment of cancer stem cells
WO2013063229A1 (en) * 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
WO2013071247A1 (en) 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
WO2013071066A1 (en) * 2011-11-11 2013-05-16 The Broad Institute, Inc. Signatures associated with the response to cancer therapy
CN103127052A (zh) * 2011-12-05 2013-06-05 维瑞斯特姆有限公司 治疗组合物和相关使用方法
CN103193841A (zh) 2012-01-06 2013-07-10 维瑞斯特姆有限公司 治疗性化合物及相关使用方法
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
US20150017134A1 (en) * 2012-03-01 2015-01-15 Whitehead Institute For Biomedical Research Emt-inducing transcription factors cooperate with sox9
JP6429191B2 (ja) * 2012-03-06 2018-11-28 セレクト バイオセラピューティクス リミテッド アポトーシスシグナル伝達抵抗性細胞を選択する装置および方法ならびにその使用
US9080154B1 (en) * 2012-04-02 2015-07-14 Bowling Green State University Cancer stem cell survivor lines
KR101463183B1 (ko) 2012-06-05 2014-11-21 연세대학교 산학협력단 암 줄기세포 특성에 기초한 암의 신규한 치료용 타겟 및 바이오마커
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
WO2014009245A2 (en) * 2012-07-09 2014-01-16 Qithera Gmbh Novel drug target indentification methods
NZ727295A (en) * 2012-08-09 2018-06-29 Celgene Corp Treatment of immune-related and inflammatory diseases
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
WO2014074805A1 (en) 2012-11-08 2014-05-15 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
EP2972381A2 (en) * 2013-03-14 2016-01-20 Galapagos NV Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition
WO2015140296A2 (en) * 2014-03-20 2015-09-24 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
EP2921855A1 (en) * 2014-03-20 2015-09-23 Centre National de la Recherche Scientifique (CNRS) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
WO2015171339A1 (en) * 2014-05-06 2015-11-12 The Board Of Regents Of The University Of Texas System Identification and isolation of neural stem cells and neurosphere initiating cells
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US10245266B2 (en) 2014-05-19 2019-04-02 Celgene Corporation 3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
JP6277894B2 (ja) * 2014-07-08 2018-02-14 株式会社島津製作所 上皮間葉転換の有無を判別する方法
WO2016047688A1 (ja) * 2014-09-24 2016-03-31 国立研究開発法人国立がん研究センター 扁平上皮がんに対する化学放射線療法の有効性を評価するための方法
US20170304251A1 (en) * 2014-10-09 2017-10-26 Paul Anthony Spagnuolo Avocado-derived lipids for use in treating leukemia
EP3026122A1 (en) * 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
GB201421094D0 (en) * 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421092D0 (en) * 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
WO2016098041A1 (en) * 2014-12-18 2016-06-23 Saarum Sciences Private Ltd Establishment and use of an in vitro platform for emt
EP3415149A1 (en) * 2015-05-14 2018-12-19 NuCana plc Cancer treatments
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
US10146914B1 (en) * 2018-03-01 2018-12-04 Recursion Pharmaceuticals, Inc. Systems and methods for evaluating whether perturbations discriminate an on target effect
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
CN109512833B (zh) * 2018-12-04 2020-10-30 天津医科大学总医院 E2f6抑制剂的功能与用途
WO2021188849A1 (en) * 2020-03-20 2021-09-23 University Of Houston System Methods and compositions for treating inflammatory and fibrotic pulmonary disorders
US12116637B2 (en) 2020-07-24 2024-10-15 The Regents Of The University Of Michigan Compositions and methods for detecting and treating high grade subtypes of uterine cancer
WO2022059026A1 (en) * 2020-09-21 2022-03-24 Mestastop Solutions Private Limited Systems and methods for predicting cancer metastasis and screening of drugs
CN117347621B (zh) * 2023-08-25 2024-03-12 广东省农业科学院农业生物基因研究中心 一种用蛋白模拟抗原-纳米抗体检测黄曲霉毒素b1的方法
WO2025170878A1 (en) * 2024-02-05 2025-08-14 Exvivo Labs Inc Methods for high-throughput drug screens at clonal resolution

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101925A2 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
WO2007035744A1 (en) * 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
EP0336248A1 (de) 1988-03-31 1989-10-11 Hoechst Aktiengesellschaft Am F-Ring substituierte Nigericinderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und Verwendung derselben als antiviral wirksam und antibakteriell wirksame Substanzen
EP0346760A2 (de) 1988-06-14 1989-12-20 Hoechst Aktiengesellschaft Nigericinderivate, Verfahren zu deren Herstellung, diese enthaltende Mittel und Verwendung derselben
DE3829450A1 (de) 1988-08-31 1990-03-01 Hoechst Ag Nigericinderivate, verfahren zu deren herstellung, diese enthaltende mittel und verwendung derselben
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5229415A (en) 1992-03-24 1993-07-20 Merck & Co., Inc. Alkylthio alkyl avermectins are active antiparasitic agents
GB9312154D0 (en) 1993-06-12 1993-07-28 Pfizer Ltd Antiparasitic agents
US20020042079A1 (en) * 1994-02-01 2002-04-11 Sanford M. Simon Methods and agents for measuring and controlling multidrug resistance
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
DK1001962T3 (da) 1997-07-23 2002-12-16 Pfizer Fremstilling af avermectinforbindelser
US8334238B2 (en) 1998-04-17 2012-12-18 Rigel, Inc. Multiparameter FACS assays to detect alterations in cellular parameters and to screen small molecule libraries
US20040101936A1 (en) 2000-02-24 2004-05-27 Hirofumi Endo Process for producing avermectin derivative
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
CA2464311A1 (en) 2001-10-26 2003-05-01 Centre National De La Recherche Scientifique Derivatives of etoposide and analogs, and pharmaceutical compositions containing them
TW200300416A (en) 2001-11-27 2003-06-01 Bristol Myers Squibb Co Method of synthesizing a paclitaxel derivative
WO2003048166A1 (en) 2001-12-03 2003-06-12 Universitätsklinikum Charite Der Humboldt-Universität Zu Berlin Technologie Transferstelle Podophyllotoxins as antiproliferative agents
US6566393B1 (en) 2002-06-21 2003-05-20 The University Of North Carolina At Chapel Hill Etoposide analogs and methods of use thereof
US7176236B2 (en) 2002-06-21 2007-02-13 University Of North Carolina At Chapel Hill Water-soluble etoposide analogs and methods of use thereof
US20050026866A1 (en) 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
EP1732911A2 (en) 2004-02-24 2006-12-20 Chatham Biotec Ltd. Semi-synthesis of taxane intermediates and aziridine analogues and their conversion to paclitaxel and docetaxel
EP2803357B1 (en) * 2004-06-25 2020-11-18 The Johns-Hopkins University Angiogenesis inhibitors
US20060040980A1 (en) * 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
WO2007005611A2 (en) 2005-06-30 2007-01-11 Whitehead Institute Progenitor cells and uses thereof
US8653083B2 (en) * 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
DE102007007750A1 (de) 2006-08-17 2008-02-21 Bayer Cropscience Ag Avermectinderivate
FR2906465B1 (fr) 2006-09-28 2008-11-28 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques chez l'homme
CA2676292C (en) * 2007-02-01 2017-09-19 Dana-Farber Cancer Institute, Inc. Cell co-culture systems and uses thereof
WO2009025854A1 (en) * 2007-08-22 2009-02-26 Burnham Institute For Medical Research Smips: small molecule inhibitors of p27 depletion in cancers and other proliferative diseases
US20100162416A1 (en) * 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006101925A2 (en) * 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20070105133A1 (en) * 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007035744A1 (en) * 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E.M.HURT ET AL: "CD44+CD24-prostate cells are aerly cancer progenitor/stem cells that provide a model for patients with poor prognosis", 《BRITISH JOURNAL OF CANCER》 *
J WANG等: "Twist, a Master Regulator of Morphogenesis,Plays an Essential Role in Tumor Metastasis", 《CELL》 *
J.M.LEE ET AL: "The epithelial-mesenchymal transition: new insights in signaling,development,and disease", 《THE JOURNAL OF CELL BIOLOGY》 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103243074B (zh) * 2012-02-14 2014-10-01 中国科学院动物研究所 一种人结直肠癌肿瘤细胞系及其制备方法和应用
CN103243074A (zh) * 2012-02-14 2013-08-14 中国科学院动物研究所 一种人结直肠癌肿瘤细胞系及其制备方法和应用
CN104840961A (zh) * 2014-02-14 2015-08-19 马立伟 癌症干细胞敏感剂在制备抗癌症干细胞试剂盒中的应用
CN106461676A (zh) * 2014-03-17 2017-02-22 新加坡科技研究局 基于核因子κB易位预测化合物的毒性的方法
CN106461676B (zh) * 2014-03-17 2019-07-05 新加坡科技研究局 基于核因子κB易位预测化合物的毒性的方法
CN104725511A (zh) * 2015-02-16 2015-06-24 华南农业大学 一种猪肠道干细胞的分离培养方法
CN104725511B (zh) * 2015-02-16 2018-01-12 华南农业大学 一种猪肠道干细胞的分离培养方法
CN108513537A (zh) * 2015-09-23 2018-09-07 米纳瓦生物技术公司 筛选分化干细胞的试剂的方法
CN106701886A (zh) * 2016-12-16 2017-05-24 管晓翔 一种三阴性乳腺癌细胞上皮间质转换过程中对内皮细胞分泌功能影响的检测方法
CN111278443A (zh) * 2017-11-08 2020-06-12 丹娜法伯癌症研究院 使用rhoa显性负型治疗癌症的组合物和方法
CN111886499A (zh) * 2017-12-21 2020-11-03 瓦尔希伯伦私人肿瘤研究基金会 基于检测肿瘤细胞中rad51焦点的方法
CN108410986A (zh) * 2018-02-26 2018-08-17 中国人民解放军总医院 Cdh6促进骨肉瘤生长和转移
CN108410986B (zh) * 2018-02-26 2021-06-22 中国人民解放军总医院 Cdh6促进骨肉瘤生长和转移
CN110082536A (zh) * 2019-04-17 2019-08-02 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用
CN110082536B (zh) * 2019-04-17 2022-06-10 广州医科大学附属肿瘤医院 一种乳腺癌细胞标志物细胞因子群及其应用
CN116783487A (zh) * 2020-08-05 2023-09-19 乔斯林糖尿病中心公司 终末期肾病生物标记物组
CN112730840A (zh) * 2021-01-29 2021-04-30 章毅 鉴别cd44和cd24分子表型的方法
CN112730840B (zh) * 2021-01-29 2023-10-17 章毅 鉴别cd44和cd24分子表型的方法
CN113125689A (zh) * 2021-03-29 2021-07-16 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用
CN113125689B (zh) * 2021-03-29 2022-02-22 创芯国际生物科技(广州)有限公司 一种新型mtt细胞活力检测试剂盒及其应用
CN114181102A (zh) * 2021-11-10 2022-03-15 深圳市检验检疫科学研究院 己雷琐辛半抗原、人工抗原、抗体及其合成方法和应用
CN114181102B (zh) * 2021-11-10 2023-06-23 深圳市检验检疫科学研究院 己雷琐辛半抗原、人工抗原、抗体及其合成方法和应用
CN116286658A (zh) * 2022-09-26 2023-06-23 南通大学 Traf5抑制剂在制备人恶性黑色素瘤治疗药物中的应用
CN115992240A (zh) * 2022-10-28 2023-04-21 中山大学附属第三医院 E2f转录因子2作为治疗靶点在制备预防和/或治疗多发性骨髓瘤的药物中的应用
CN115948558A (zh) * 2023-01-19 2023-04-11 重庆医科大学 乳腺癌肺特异性转移的标志物及其药物组合物与应用

Also Published As

Publication number Publication date
JP2014128294A (ja) 2014-07-10
EP2385370A1 (en) 2011-11-09
WO2009126310A2 (en) 2009-10-15
US20110191868A1 (en) 2011-08-04
JP2011522515A (ja) 2011-08-04
US20140294729A1 (en) 2014-10-02
CA2723648A1 (en) 2009-10-15
EP2274617A4 (en) 2011-11-09
EP2274617A2 (en) 2011-01-19
WO2009126310A3 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
CN102144163A (zh) 关于鉴定和使用靶向癌症干细胞的试剂的方法
Bi et al. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance
Testa et al. Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells
JP6599334B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
EP3021120A1 (en) Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
US20150212065A1 (en) Methods using Axl as a biomarker of epithelial-to-mesenchymal transition
Bianco et al. GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
JP7719135B2 (ja) 微小残存がんを治療する方法
JP6109951B2 (ja) 結腸癌の処置および診断
US20100273660A1 (en) ONCOGENOMICS-BASED RNAi SCREEN AND USE THEREOF TO IDENTIFY NOVEL TUMOR SUPPRESSORS
Lehrich et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
CN116368384A (zh) 用于巨噬细胞调节的化合物、靶标和途径
US8936941B2 (en) Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
Kim et al. Sustained oncogenic signaling in the cytostatic state enables targeting of nonproliferating persistent cancer cells
HK1164438A (en) Methods for identification and use of agents targeting cancer stem cells
Fonseca Understanding PLK4’s Role in Cancer
Cabel Identification and Characterization of CLK3 in the Colonic Epithelium as a Regulator of the Wnt Pathway
WO2026013153A1 (en) Methods of prognosis and treatment of patients suffering from myc-high tumors
Zhang Zombie: A Soluble Signal Emitted by Dying Cells that Drives Neoplastic Transformation
La Pierre Investigating the Functional Significance of the MNK1/LARP1 Interaction in Breast Cancer
Ceccotti In vivo modeling and characterization of MYC/BCL2 Double Hit Lymphoma
Meskyte Identification of the role of transcription factor ETV7 in breast cancer aggressiveness
CN118021968A (zh) 过表达klf15的物质在制备用于治疗或辅助治疗胰腺导管腺癌的产品中的应用
Chung Targeting cell cycle checkpoints in triple negative breast cancer and pancreatic ductal adenocarcinoma
Fils-Aimé Understanding the Tgf-β Language or Getting Lost in Translation: The TGF-β MicroRNAome

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH HARVAR

Free format text: FORMER OWNER: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH

Effective date: 20140709

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140709

Address after: Massachusetts, USA

Applicant after: Massachusetts Institute of Technology

Applicant after: Whitehead Institute for Biomedical Research

Applicant after: Harvard Institute and director

Address before: Massachusetts, USA

Applicant before: Massachusetts Institute of Technology

Applicant before: Whitehead Institute for Biomedical Research

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: Massachusetts Institute of Technology

Applicant after: Whitehead Institute for Biomedical Research

Applicant after: PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Address before: Massachusetts, USA

Applicant before: Massachusetts Institute of Technology

Applicant before: Whitehead Institute for Biomedical Research

Applicant before: Harvard Institute and director

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110803